Circadian Technology granted significant European patent Circadian Technologies Limited announced today that it is subsidiary company, Vegenics Limited, offers been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a wide spectrum of therapeutic indications, including the treatment of tumor information-om-finasterid.html . Related StoriesMeat-rich diet plan may increase kidney cancers riskMD Anderson study reveals why chemotherapy drugs not effective for many pancreatic tumor patientsViralytics enters into scientific trial collaboration contract with MSDThis European patent alongside the VEGF-D patent granted in the United States last year provides Circadian with a major commercial advantage and usage of the world’s two largest markets.
While grafting success has improved significantly in the last 20 years you may still find numerous grafts which continue to fail. Our findings demonstrating that VEGF-C is normally up-regulated in graft failure and that blockade of VEGF-C could significantly improve graft survival identify VEGF-C blockade as a thrilling new therapeutic likelihood for improving corneal graft survival. Mr. Robert Klupacs, CEO of Circadian Technology, said: This extremely exciting data generated by our collaborators at Schepens provides a significant new therapeutic development chance of our VGX-100 program furthermore to your ongoing clinical oncology applications. We are currently undertaking additional preclinical studies with VGX-100 in the corneal grafting setting with the aim to commence clinical trials in H1 2013.